Regeneron Pharmaceuticals (MIL:1REGN) Long-Term Debt : €1,788 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Regeneron Pharmaceuticals Long-Term Debt?

Regeneron Pharmaceuticals's Long-Term Debt for the quarter that ended in Sep. 2024 was €1,788 Mil.

Regeneron Pharmaceuticals's quarterly Long-Term Debt increased from Mar. 2024 (€1,825 Mil) to Jun. 2024 (€1,843 Mil) but then declined from Jun. 2024 (€1,843 Mil) to Sep. 2024 (€1,788 Mil).

Regeneron Pharmaceuticals's annual Long-Term Debt increased from Dec. 2021 (€1,752 Mil) to Dec. 2022 (€1,870 Mil) but then declined from Dec. 2022 (€1,870 Mil) to Dec. 2023 (€1,818 Mil).

Regeneron Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Regeneron Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Long-Term Debt Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

1,626.33

1,752.30

1,870.44

1,818.32

Regeneron Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial															1,857.70	1,818.32	1,824.64	1,842.76	1,787.58

Regeneron Pharmaceuticals (MIL:1REGN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Regeneron Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIL:1REGN) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines